Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models

Ji Ae Kim, Rak Kyun Seong, Mukesh Kumar, Ok Shin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.

Original languageEnglish
Article number72
JournalViruses
Volume10
Issue number2
DOIs
Publication statusPublished - 2018 Feb 9

Fingerprint

Ribavirin
Virus Replication
Cell Death
Stem Cells
Myelitis
Microcephaly
Meningoencephalitis
Vero Cells
B-Cell Lymphoma
Zika Virus
favipiravir
Real-Time Polymerase Chain Reaction
Therapeutics
Public Health
Fibroblasts
Phosphorylation
Skin

Keywords

  • Anti-viral
  • Favipiravir
  • HNPCs
  • Ribavirin
  • Zika virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models. / Kim, Ji Ae; Seong, Rak Kyun; Kumar, Mukesh; Shin, Ok.

In: Viruses, Vol. 10, No. 2, 72, 09.02.2018.

Research output: Contribution to journalArticle

@article{f9576fd847e2482191c54ec96fce8eb3,
title = "Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models",
abstract = "Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barr{\'e} syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.",
keywords = "Anti-viral, Favipiravir, HNPCs, Ribavirin, Zika virus",
author = "Kim, {Ji Ae} and Seong, {Rak Kyun} and Mukesh Kumar and Ok Shin",
year = "2018",
month = "2",
day = "9",
doi = "10.3390/v10020072",
language = "English",
volume = "10",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models

AU - Kim, Ji Ae

AU - Seong, Rak Kyun

AU - Kumar, Mukesh

AU - Shin, Ok

PY - 2018/2/9

Y1 - 2018/2/9

N2 - Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.

AB - Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.

KW - Anti-viral

KW - Favipiravir

KW - HNPCs

KW - Ribavirin

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85041913498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041913498&partnerID=8YFLogxK

U2 - 10.3390/v10020072

DO - 10.3390/v10020072

M3 - Article

C2 - 29425176

AN - SCOPUS:85041913498

VL - 10

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 2

M1 - 72

ER -